サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：インターロイキン-6（IL-6）阻害剤市場、シェア、規模、動向、産業分析レポート：薬剤タイプ別；疾患タイプ別；流通チャネル別；地域別；セグメント予測、2023-2032年
市場調査レポート
商品コード
1346913

インターロイキン-6（IL-6）阻害剤市場、シェア、規模、動向、産業分析レポート：薬剤タイプ別；疾患タイプ別；流通チャネル別；地域別；セグメント予測、2023-2032年

Interleukin-6 (IL-6) Inhibitors Market Share, Size, Trends, Industry Analysis Report, By Drug Type (Tocilizumab, Siltuximab, and Sylvant); By Disease Type; By Distribution Channel; By Region; Segment Forecast, 2023-2032
出版日: | 発行: Polaris Market Research | ページ情報: 英文 118 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.70円
インターロイキン-6（IL-6）阻害剤市場、シェア、規模、動向、産業分析レポート：薬剤タイプ別；疾患タイプ別；流通チャネル別；地域別；セグメント予測、2023-2032年
出版日: 2023年08月23日
発行: Polaris Market Research
ページ情報: 英文 118 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Polaris Market Research社の最新調査によると、インターロイキン-6（IL-6）阻害剤の世界市場規模は2032年までに863億1,000万米ドルに達する見込みです。このレポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

インターロイキン-6（IL-6）阻害剤の人気の高まりにより、企業や多くの組織が研究開発に投資しています。例えば、2022年12月、静脈内（IV）投与のトシリズマブ（アクテムラ）は、特例措置を受けている入院患者におけるCOVID-19の管理薬として米国食品医薬品局（FDA）から認可されました。トシリズマブは、パンデミックウイルスの治療薬としてFDAから承認された最初のモノクローナル抗体であり、これはロシュの承認によるものです。これに加えて2021年9月、ヘテロはインド医薬品監督庁（DCGI）から、入院患者向けのCOVID-19治療薬であるトシリズマブのバイオシミラー版の販売承認を得た。複数の団体や業界参入企業の貢献が、世界市場の成長を大きく後押ししています。

自己免疫疾患や炎症性疾患の有病率の増加は、世界市場の開拓に拍車をかけると思われます。IL-6は、関節リウマチ、若年性特発性関節炎、キャッスルマン病、サイトカイン放出症候群（CRS）など、さまざまな自己免疫疾患や炎症性疾患の発症において重要な役割を果たしています。これらの疾患の有病率が世界的に上昇していることが、IL-6阻害剤のような効果的な治療薬に対する需要を押し上げています。

慢性炎症性疾患の有病率の増加は、市場の世界の成長を促進する主な要因の一つです。関節リウマチ、若年性特発性関節炎、キャッスルマン病などの慢性炎症性疾患が世界的に増加しています。例えば、北米と欧州では、子供1万人のうち4～16人が若年性特発性関節炎に罹患していると推定されています。IL-6阻害剤は、これらの疾患の症状や進行の管理に有効であることが示されており、IL-6阻害剤の需要を牽引しています。このため、世界市場の開拓が進んでいます。

インターロイキン-6（IL-6）阻害剤市場レポート・ハイライト

トシリズマブ（Tocilizumab）は、最初に承認され市場に参入したIL-6阻害剤の1つであるため、2022年には最大の市場シェアを記録すると予想されます。

関節リウマチは比較的有病率が高いため、世界市場で最大の売上を獲得する見込み

専門小売店はIL-6阻害薬の重要な流通チャネルであるため、2022年度の世界売上高で最大のシェアを占める

北米は、企業や団体による臨床試験の増加や業界における研究開発の急増により、2022年時点で最大のシェアを占めています。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界のインターロイキン6（IL-6）阻害剤市場に関する洞察

  • インターロイキン6（IL-6）阻害剤市場- 流通チャネルのスナップショット
  • インターロイキン-6（IL-6）阻害剤の市場力学
    • 促進要因と機会
      • 関節リウマチ（RA）の有病率の増加
      • 人気の高いインターロイキン6阻害剤
    • 抑制要因と課題
      • 開発費が高い
  • PESTEL分析
  • インターロイキン6（IL-6）阻害剤市場流通チャネルの動向
  • バリューチェーン分析
  • COVID-19感染症の影響分析

第5章 疾患の種類別の世界のインターロイキン6（IL-6）阻害剤市場

  • 主な調査結果
  • イントロダクション
  • 関節リウマチ
  • キャッスルマン病
  • がん（腎がん、前立腺がん）
  • 動脈炎

第6章 世界のインターロイキン6（IL-6）阻害剤市場、薬剤の種類別

  • 主な調査結果
  • イントロダクション
  • トシリズマブ
  • シルツキシマブ
  • シルバント

第7章 世界のインターロイキン6（IL-6）阻害剤市場、流通チャネル別

  • 主な調査結果
  • イントロダクション
  • 小売薬局
  • 病院薬局
  • 専門薬局
  • オンライン薬局
  • その他の販売チャネル

第8章 世界のインターロイキン6（IL-6）阻害剤市場、地域別

  • 主な調査結果
  • イントロダクション
    • インターロイキン6（IL-6）阻害剤市場評価、地域、2019-2032
  • インターロイキン6（IL-6）阻害剤市場-北米
    • 北米：インターロイキン6（IL-6）阻害剤市場、疾患タイプ別、2019年～2032年
    • 北米：インターロイキン6（IL-6）阻害剤市場、流通チャネル別、2019-2032
    • 北米：インターロイキン-6（IL-6）阻害剤市場、薬剤タイプ別、2019-2032
    • インターロイキン6（IL-6）阻害剤市場-米国
    • インターロイキン6（IL-6）阻害剤市場- カナダ
  • インターロイキン6（IL-6）阻害剤市場- 欧州
    • 欧州：インターロイキン6（IL-6）阻害剤市場、疾患タイプ別、2019～2032年
    • 欧州：インターロイキン6（IL-6）阻害剤市場、流通チャネル別、2019-2032
    • 欧州：インターロイキン6（IL-6）阻害剤市場、薬剤タイプ別、2019～2032年
    • インターロイキン6（IL-6）阻害剤市場- 英国
    • インターロイキン6（IL-6）阻害剤市場- フランス
    • インターロイキン6（IL-6）阻害剤市場- ドイツ
    • インターロイキン6（IL-6）阻害剤市場- イタリア
    • インターロイキン6（IL-6）阻害剤市場- スペイン
    • インターロイキン6（IL-6）阻害剤市場- オランダ
    • インターロイキン6（IL-6）阻害剤市場- ロシア
  • インターロイキン6（IL-6）阻害剤市場- アジア太平洋
    • アジア太平洋地域：インターロイキン6（IL-6）阻害剤市場、疾患タイプ別、2019～2032年
    • アジア太平洋：インターロイキン6（IL-6）阻害剤市場、流通チャネル別、2019～2032年
    • アジア太平洋：インターロイキン6（IL-6）阻害剤市場、薬剤タイプ別、2019～2032年
    • インターロイキン6（IL-6）阻害剤市場- 中国
    • インターロイキン6（IL-6）阻害剤市場- インド
    • インターロイキン6（IL-6）阻害剤市場- マレーシア
    • インターロイキン6（IL-6）阻害剤市場- 日本
    • インターロイキン6（IL-6）阻害剤市場- インドネシア
    • インターロイキン6（IL-6）阻害剤市場- 韓国
  • インターロイキン6（IL-6）阻害剤市場-中東およびアフリカ
    • 中東およびアフリカ：インターロイキン6（IL-6）阻害剤市場、疾患タイプ別、2019～2032年
    • 中東およびアフリカ：インターロイキン6（IL-6）阻害剤市場、流通チャネル別、2019～2032年
    • 中東およびアフリカ：インターロイキン6（IL-6）阻害剤市場、薬剤タイプ別、2019～2032年
    • インターロイキン6（IL-6）阻害剤市場- サウジアラビア
    • インターロイキン6（IL-6）阻害剤市場- アラブ首長国連邦
    • インターロイキン6（IL-6）阻害剤市場- イスラエル
    • インターロイキン6（IL-6）阻害剤市場- 南アフリカ
  • インターロイキン6（IL-6）阻害剤市場-ラテンアメリカ
    • ラテンアメリカ：インターロイキン-6（IL-6）阻害剤市場、疾患タイプ別、2019-2032
    • ラテンアメリカ：インターロイキン-6（IL-6）阻害剤市場、流通チャネル別、2019-2032
    • ラテンアメリカ：インターロイキン-6（IL-6）阻害剤市場、薬剤タイプ別、2019-2032
    • インターロイキン6（IL-6）阻害剤市場- メキシコ
    • インターロイキン6（IL-6）阻害剤市場- ブラジル
    • インターロイキン6（IL-6）阻害剤市場- アルゼンチン

第9章 競合情勢

  • 拡張と買収の分析
    • 拡大
    • 買収
  • 提携/協業/合意/公開

第10章 企業プロファイル

  • AbbVie
  • AstraZeneca
  • Bausch Health
  • Eli Lilly
  • GlaxoSmithKline
  • Johnson and Johnson Services
  • Novartis
  • Regeneron Pharmaceuticals
  • Roche
  • Teva Pharmaceutical
図表

List of Tables

  • Table 1 Global Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 2 Global Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 3 Global Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 4 Interleukin-6 (IL-6) Inhibitors Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 5 North America: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 6 North America: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 7 North America: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 8 U.S.: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 9 U.S.: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 10 U.S.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 11 Canada: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 12 Canada: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 13 Canada: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 14 Europe: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 15 Europe: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 16 Europe: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 17 UK: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 18 UK: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 19 UK: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 20 France: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 21 France: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 22 France: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 23 Germany: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 24 Germany: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 25 Germany: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 26 Italy: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 27 Italy: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 28 Italy: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 29 Spain: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 30 Spain: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 31 Spain: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 32 Netherlands: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 33 Netherlands: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 34 Netherlands: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 35 Russia: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 36 Russia: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 37 Russia: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 38 Asia Pacific: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 39 Asia Pacific: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 40 Asia Pacific: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 41 China: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 42 China: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 43 China: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 44 India: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 45 India: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 46 India: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 47 Malaysia: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 48 Malaysia: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 49 Malaysia: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 50 Japan: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 51 Japan: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 52 Japan: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 53 Indonesia: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 54 Indonesia: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 55 Indonesia: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 56 South Korea: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 57 South Korea: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 58 South Korea: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 59 Middle East & Africa: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 60 Middle East & Africa: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 61 Middle East & Africa: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 62 Saudi Arabia: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 63 Saudi Arabia: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 64 Saudi Arabia: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 65 UAE: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 66 UAE: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 67 UAE: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 68 Israel: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 69 Israel: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 70 Israel: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 71 South Africa: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 72 South Africa: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 73 South Africa: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 74 Latin America: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 75 Latin America: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 76 Latin America: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 77 Mexico: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 78 Mexico: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 79 Mexico: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 80 Brazil: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 81 Brazil: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 82 Brazil: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 83 Argentina: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 84 Argentina: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 85 Argentina: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)

List of Figures

  • Figure 1. Global Interleukin-6 (IL-6) Inhibitors Market, 2019-2032 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Drug Type
  • Figure 7. Global Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2022 & 2032 (USD Billion)
  • Figure 8. Market by Disease Type
  • Figure 9. Global Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2022 & 2032 (USD Billion)
  • Figure 10. Market by Distribution Channel
  • Figure 11. Global Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2022 & 2032 (USD Billion)
  • Figure 12. Interleukin-6 (IL-6) Inhibitors Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Figure 13. Strategic Analysis - Interleukin-6 (IL-6) Inhibitors Market
目次
Product Code: PM3720

The global interleukin-6 (IL-6) inhibitors market size is expected to reach USD 86.31 billion by 2032, according to a new study by Polaris Market Research. The report "Interleukin-6 (IL-6) Inhibitors Market Share, Size, Trends, Industry Analysis Report, By Drug Type (Tocilizumab, Siltuximab, and Sylvant); By Disease Type; By Distribution Channel; By Region; Segment Forecast, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The growing popularity of interleukin-6 (IL-6) inhibitors has led businesses and many organizations to invest in research and development. For example, in December 2022, Tocilizumab (Actemra), administered intravenously (IV), was authorized by the US Food and Drug Administration (FDA) for the management of COVID-19 in hospitalized individuals receiving extra care. Tocilizumab was the first monoclonal antibody approved by the FDA to treat the pandemic virus, thanks to the approval given to Roche. In addition to this, in September 2021, Hetero received approval from the Drug Controller General of India (DCGI) for the sale of a biosimilar version of Tocilizumab, a COVID-19 medication for hospitalized people. Contributions of several organizations and industry participants are significantly augmenting the market's growth worldwide.

The increasing prevalence of autoimmune and inflammatory diseases will likely spur the global market's development. IL-6 is critical in the pathogenesis of various autoimmune and inflammatory diseases, such as rheumatoid arthritis, juvenile idiopathic arthritis, Castleman disease, and cytokine release syndrome (CRS). The rising prevalence of these conditions worldwide drives the demand for effective therapies like IL-6 inhibitors.

The increasing prevalence of chronic inflammatory conditions is one of the primary factors likely to enhance the market's growth globally. Chronic inflammatory conditions such as rheumatoid arthritis, juvenile idiopathic arthritis, and Castleman disease are rising globally. For example, as per the estimates, 4 to 16 out of every 10,000 kids in North America and Europe will have juvenile idiopathic arthritis. IL-6 inhibitors have shown efficacy in managing the symptoms and progression of these conditions, driving the demand for IL-6 inhibitors. Henceforth, this heightens the development in the global market.

Interleukin-6 (IL-6) Inhibitors Market Report Highlights

Tocilizumab drug is anticipated to record the largest market share in the year of 2022 as it was one of the first IL-6 inhibitors to receive regulatory approval and enter the market

Rheumatoid arthritis disease type is expected to garner the largest revenue in the global market due to relatively high prevalence of the diseases

Specialty retailers segment is accounting largest market share of the global revenue in the fiscal year of 2022 as these are a key distribution channel for IL-6 inhibitors

North America held the largest share as of 2022 due to increasing clinical trials among companies and organizations and surging research and development in the industry

The global players include: AbbVie, inc., AstraZeneca, Bausch Health, Johnson and Johnson Services, Novartis, GlaxoSmithKline, Eli Lilly, Teva Pharmaceutical, Regeneron Pharmaceuticals, Roche, and others

Polaris Market Research has segmented the Interleukin-6 (IL-6) Inhibitors market report based on drug type, disease type, and distribution channel, and region:

Interleukin-6 (IL-6) Inhibitors, Type Outlook (Revenue - USD Billion, 2019-2032)

  • Tocilizumab
  • Siltuximab
  • Sylvant

Interleukin-6 (IL-6) Inhibitors, Disease Type Outlook (Revenue - USD Billion, 2019-2032)

  • Rheumatoid Arthritis
  • Castleman's disease
  • Cancers (Renal cancer, Prostate cancer)
  • Arteritis

Interleukin-6 (IL-6) Inhibitors, Distribution Channel Outlook (Revenue - USD Billion, 2019-2032)

  • Retail Pharmacies
  • Hospital pharmacies
  • Specialty pharmacies
  • Online pharmacies
  • Other Sales Channel

Interleukin-6 (IL-6) Inhibitors, Regional Outlook (Revenue - USD Billion, 2019-2032)

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Russia
    • Netherlands
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Indonesia
    • Malaysia
  • Latin America
    • Argentina
    • Brazil
    • Mexico
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • Israel
    • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Interleukin-6 (IL-6) Inhibitors Market Insights

  • 4.1. Interleukin-6 (IL-6) Inhibitors Market - Distribution Channel Snapshot
  • 4.2. Interleukin-6 (IL-6) Inhibitors Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increasing prevalence of rheumatoid arthritis (RA)
      • 4.2.1.2. High popularity of interleukin-6 inhibitor
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High development cost
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Interleukin-6 (IL-6) Inhibitors Market Distribution Channel Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Interleukin-6 (IL-6) Inhibitors Market, by Disease Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • 5.3. Rheumatoid Arthritis
    • 5.3.1. Global Interleukin-6 (IL-6) Inhibitors Market, by Rheumatoid Arthritis, by Region, 2019-2032 (USD Billion)
  • 5.4. Castleman's disease
    • 5.4.1. Global Interleukin-6 (IL-6) Inhibitors Market, by Castleman's disease, by Region, 2019-2032 (USD Billion)
  • 5.5. Cancers (Renal cancer, Prostate cancer)
    • 5.5.1. Global Interleukin-6 (IL-6) Inhibitors Market, by Cancers (Renal cancer, Prostate cancer), by Region, 2019-2032 (USD Billion)
  • 5.6. Arteritis
    • 5.6.1. Global Interleukin-6 (IL-6) Inhibitors Market, by Arteritis, by Region, 2019-2032 (USD Billion)

6. Global Interleukin-6 (IL-6) Inhibitors Market, by Drug Type

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • 6.3. Tocilizumab
    • 6.3.1. Global Interleukin-6 (IL-6) Inhibitors Market, by Tocilizumab, by Region, 2019-2032 (USD Billion)
  • 6.4. Siltuximab
    • 6.4.1. Global Interleukin-6 (IL-6) Inhibitors Market, by Siltuximab, by Region, 2019-2032 (USD Billion)
  • 6.5. Sylvant
    • 6.5.1. Global Interleukin-6 (IL-6) Inhibitors Market, by Sylvant, by Region, 2019-2032 (USD Billion)

7. Global Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 7.3. Retail Pharmacies
    • 7.3.1. Global Interleukin-6 (IL-6) Inhibitors Market, by Retail Pharmacies, By Region, 2019-2032 (USD Billion)
  • 7.4. Hospital pharmacies
    • 7.4.1. Global Interleukin-6 (IL-6) Inhibitors Market, by Hospital pharmacies, By Region, 2019-2032 (USD Billion)
  • 7.5. Specialty pharmacies
    • 7.5.1. Global Interleukin-6 (IL-6) Inhibitors Market, by Specialty pharmacies, By Region, 2019-2032 (USD Billion)
  • 7.6. Online pharmacies
    • 7.6.1. Global Interleukin-6 (IL-6) Inhibitors Market, by Online pharmacies, By Region, 2019-2032 (USD Billion)
  • 7.7. Other sales channel
    • 7.7.1. Global Interleukin-6 (IL-6) Inhibitors Market, by Other sales channel, By Region, 2019-2032 (USD Billion)

8. Global Interleukin-6 (IL-6) Inhibitors Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Interleukin-6 (IL-6) Inhibitors Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 8.3. Interleukin-6 (IL-6) Inhibitors Market - North America
    • 8.3.1. North America: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.3.2. North America: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.3.3. North America: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.3.4. Interleukin-6 (IL-6) Inhibitors Market - U.S.
      • 8.3.4.1. U.S.: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.3.4.2. U.S.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.3.4.3. U.S.: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.3.5. Interleukin-6 (IL-6) Inhibitors Market - Canada
      • 8.3.5.1. Canada: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.3.5.2. Canada.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.3.5.3. Canada: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • 8.4. Interleukin-6 (IL-6) Inhibitors Market - Europe
    • 8.4.1. Europe: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.4.2. Europe.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.4.3. Europe: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.4.4. Interleukin-6 (IL-6) Inhibitors Market - UK
      • 8.4.4.1. UK: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.4.4.2. UK.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.4.3. UK: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.4.5. Interleukin-6 (IL-6) Inhibitors Market - France
      • 8.4.5.1. France: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.4.5.2. France.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.5.3. France: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.4.6. Interleukin-6 (IL-6) Inhibitors Market - Germany
      • 8.4.6.1. Germany: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.4.6.2. Germany.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.6.3. Germany: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.4.7. Interleukin-6 (IL-6) Inhibitors Market - Italy
      • 8.4.7.1. Italy: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.4.7.2. Italy.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.7.3. Italy: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.4.8. Interleukin-6 (IL-6) Inhibitors Market - Spain
      • 8.4.8.1. Spain: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.4.8.2. Spain.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.8.3. Spain: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.4.9. Interleukin-6 (IL-6) Inhibitors Market - Netherlands
      • 8.4.9.1. Netherlands: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.4.9.2. Netherlands.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.9.3. Netherlands: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.4.10. Interleukin-6 (IL-6) Inhibitors Market - Russia
      • 8.4.10.1. Russia: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.4.10.2. Russia.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.10.3. Russia: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • 8.5. Interleukin-6 (IL-6) Inhibitors Market - Asia Pacific
    • 8.5.1. Asia Pacific: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.5.2. Asia Pacific.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.5.3. Asia Pacific: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.5.4. Interleukin-6 (IL-6) Inhibitors Market - China
      • 8.5.4.1. China: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.5.4.2. China.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.4.3. China: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.5.5. Interleukin-6 (IL-6) Inhibitors Market - India
      • 8.5.5.1. India: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.5.5.2. India.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.5.3. India: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.5.6. Interleukin-6 (IL-6) Inhibitors Market - Malaysia
      • 8.5.6.1. Malaysia: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.5.6.2. Malaysia.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.6.3. Malaysia: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.5.7. Interleukin-6 (IL-6) Inhibitors Market - Japan
      • 8.5.7.1. Japan: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.5.7.2. Japan.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.7.3. Japan: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.5.8. Interleukin-6 (IL-6) Inhibitors Market - Indonesia
      • 8.5.8.1. Indonesia: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.5.8.2. Indonesia.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.8.3. Indonesia: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.5.9. Interleukin-6 (IL-6) Inhibitors Market - South Korea
      • 8.5.9.1. South Korea: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.5.9.2. South Korea.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.9.3. South Korea: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • 8.6. Interleukin-6 (IL-6) Inhibitors Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.6.2. Middle East & Africa.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.6.3. Middle East & Africa: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.6.4. Interleukin-6 (IL-6) Inhibitors Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.6.4.2. Saudi Arabia.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.6.5. Interleukin-6 (IL-6) Inhibitors Market - UAE
      • 8.6.5.1. UAE: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.6.5.2. UAE.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.6.5.3. UAE: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.6.6. Interleukin-6 (IL-6) Inhibitors Market - Israel
      • 8.6.6.1. Israel: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.6.6.2. Israel.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.6.6.3. Israel: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.6.7. Interleukin-6 (IL-6) Inhibitors Market - South Africa
      • 8.6.7.1. South Africa: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.6.7.2. South Africa.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.6.7.3. South Africa: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • 8.7. Interleukin-6 (IL-6) Inhibitors Market - Latin America
    • 8.7.1. Latin America: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.7.2. Latin America.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.7.3. Latin America: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.7.4. Interleukin-6 (IL-6) Inhibitors Market - Mexico
      • 8.7.4.1. Mexico: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.7.4.2. Mexico.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.7.4.3. Mexico: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.7.5. Interleukin-6 (IL-6) Inhibitors Market - Brazil
      • 8.7.5.1. Brazil: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.7.5.2. Brazil.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.7.5.3. Brazil: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.7.6. Interleukin-6 (IL-6) Inhibitors Market - Argentina
      • 8.7.6.1. Argentina: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.7.6.2. Argentina.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.7.6.3. Argentina: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. AbbVie
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. AstraZeneca
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Bausch Health
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Eli Lilly
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. GlaxoSmithKline
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Johnson and Johnson Services
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Novartis
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Regeneron Pharmaceuticals
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Roche
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Teva Pharmaceutical
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development